Research-stage & investigational. No clinical or field-performance claims.
NeuroRelief-P™ Peptide innovation for pain modulation, engineered to relieve chronic and neuropathic pain without systemic risks.
NeuroRegen-P™ Activates regenerative signaling to drive axonal growth and synaptic repair for injury and degenerative conditions.
NeuroReset-P™ Stabilizes neural circuits and supports recovery from substance dependency through structural and biochemical rebalancing.
Patent Pending – PATP1280.03
Neuroscience R&D researching mechanism-first platform developments across neural recovery biology, scaffold innovation, and neuroresilience pathways.
NeuroReset™ AI-Assisted Technical Review NeuroReset™ is presented within the BII portfolio as a research-stage, patent-pending investigational platform focused on recovery-related central nervous system biology. The PATP1280.03 technical review examines a multi-site targeted therapeutic conjugate designed for coordinated intracellular release of two pharmacologically complementary ligands, with investigational focus on neuroinflammation, post-dependency cognitive recovery, mood dysregulation, and relapse vulnerability.
Neurophorol™ AI-Assisted Technical Review Neurophorol™ is a research-stage, patent-pending investigational platform within the Biotech International Institute portfolio. The PATP1280.01 filing is centered on a novel family of CB2-selective xanthene-core cannabinoid analogs designed to explore non-psychoactive cannabinoid-inspired biology through a differentiated structural framework.
Mycophorol™ AI-Assisted Technical Review. Mycophorol™ is a research-stage, patent-pending investigational platform within the Biotech International Institute portfolio. The PATP1280.04 filing is centered on a multi-site targeting therapeutic conjugate designed to explore durable, balanced neural recovery in the context of post-inflammation, trauma, or addiction-related biological disruption.
